New treatment strategies for IgA nephropathy
TANG Chen
LIU Li-jun
Abstract：IgA nephropathy(IgAN)is a common glomerular disease worldwide.With current treatments,nearly half of the patients will develop renal failure ten years after the onset of the disease,and there is an urgent need for new therapies.In recent years,with the in-depth research on its pathogenesis,significant progress has been made,especially in key aspects such as the synthesis of pathogenic IgA and complement activation.A number of new drugs have been approved for clinical application.These include the first approved drug for mucosal immunity,a targeted-release formulation(TRF)of budesonide,the regulators targeting the activity of B cells and plasma cells,as well as drugs targeting the complement pathway.All of these drugs have shown the effects of reducing proteinuria in IgAN and delaying the progression of kidney diseases in previous trials.In the future,personalized and multi-target combination therapies are expected to further improve the prognosis of patients.
Keywords：IgA nephropathytargeted therapymucosal immunitycomplement pathway
Publication Date：2025-03-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 188-193 )